Table 1.
Concentration of anticancer drugs between water and lipid carrier solutions during HIPEC
| Anticancer drugs | Mitomycin-C | |||||
|---|---|---|---|---|---|---|
| Estimated samples | Plasma | Peritoneal fluid | ||||
| Carrier solutions | Drug concentration (ng/mL) | Overall p value† | Drug concentration (ng/mL) | Overall p value† | ||
| Time | Dianeal® (n = 3) | Lipid solution (n = 3) | Dianeal® (n = 3) | Lipid solution (n = 3) | ||
| 0 | 0 ± 0 | 0 ± 0 | Carrier solution: p = 0.0419 Time: p < 0.0001 Carrier solution · time: p = 0.0332 |
4129.5 ± 562.1 | 5637.4 ± 353.7 | Carrier solution: p = 0.1447 Time: p < 0.0001 Carrier solution · time: p = 0.2313 |
| 5 | 52 ± 4.0 | 33.5 ± 0.1 | 3687.6 ± 399.5 | 5110.3 ± 1190.9 | ||
| 10 | 83.8 ± 9.5 | 54.0 ± 14.1 | 3532.3 ± 229.7 | 3651.0 ± 946.7 | ||
| 20 | 105.9 ± 5.1 | 54.2 ± 5.7 | 3234.5 ± 421.0 | 3372.3 ± 362.2 | ||
| 30 | 122.3 ± 3.8 | 58.1 ± 13.0 | 2440.7 ± 197.0 | 2776.2 ± 318.0 | ||
| 45 | 173.8 ± 22.2 | 61.1 ± 6.1 | 1982.2 ± 233.5 | 2380.9 ± 351.0 | ||
| 60 | 203.3 ± 18.7 | 60.0 ± 9.7 | 1515.8 ± 178.7 | 2366.9 ± 204.3 | ||
| Anticancer drugs | Oxaliplatin | |||||||
|---|---|---|---|---|---|---|---|---|
| Estimated samples | Plasma | Peritoneal fluid | ||||||
| Carrier solutions | Drug concentration (ng/mL) | Overall p value† | Drug concentration (ng/mL) | Overall p value† | ||||
| Time | Dianeal® (n = 3) | 5% Dextrose (n = 3) | Lipid solution (n = 3) | Dianeal® (n = 3) | 5% Dextrose (n = 3) | Lipid solution (n = 3) | ||
| 0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | Carrier solution: p = 0.0048 Time: p < 0.0001 Carrier solution · time: p = 0.0049 |
34,053.1 ± 1020.0 | 34172.5 ± 2721.1 | 24,162.1 ± 6562.2 | Carrier solution: p = 0.0307 Time: p = 0.7322 Carrier solution · time: p = 0.6249 |
| 5 | 331.3 ± 3.8 | 633.2 ± 121.6 | 276.2 ± 52.0 | 29,652.3 ± 2882.0 | 33,323.1 ± 6834.2 | 23,444.7 ± 6613.9 | ||
| 10 | 433.2 ± 121.0 | 892.4 ± 447.7 | 440.4 ± 112.0 | 27,671.9 ± 2273.3 | 32,907.0 ± 3919.8 | 25,220.9 ± 6078.8 | ||
| 20 | 928.5 ± 240.1 | 2548.6 ± 1406.8 | 906.7 ± 363.5 | 30,573.2 ± 5042.3 | 29,145.2 ± 2315.7 | 25,870.7 ± 6310.5 | ||
| 30 | 1503.9 ± 555.1 | 3045.5 ± 397.9 | 1129.6 ± 428.9 | 28,737.9 ± 5267.0 | 31,320.5 ± 5696.8 | 29,700.3 ± 7873.8 | ||
| 45 | 2356.9 ± 1238.4 | 4627.5 ± 1346.4 | 2126.0 ± 1403.9 | 30,996.5 ± 2960.2 | 32,412.8 ± 2838.9 | 26,504.4 ± 7815.0 | ||
| 60 | 3667.1 ± 1527.2 | 7093.9 ± 946.1 | 2541.9 ± 966.1 | 27,329.7 ± 4951.2 | 30,239.3 ± 598.2 | 26,755.2 ± 8213.6 | ||
Mean ± standard deviation
†The linear mixed model was used to calculate p values and to compare the concentration of anticancer drugs among carrier solutions according to the time